This trial is evaluating whether XRD-0394 will improve 2 primary outcomes and 8 secondary outcomes in patients with Metastasis. Measurement will happen over the course of Day 2 of RT regimen.
This trial requires 38 total participants across 4 different treatment groups
This trial involves 4 different treatments. XRD-0394 is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Relapse after successful treatment is a rare event for patients; therefore, it is not a reliable predictor of future disease relapse. In patients with severe disease, it is of critical importance to identify their risk factors that precipitate relapse." - Anonymous Online Contributor
"There are no signs of relapse such as fever, night sweats, weight loss or feeling tired for more than two weeks when the patient is taking antipsychotics appropriately. There will be a significant improvement after the initial exacerbation." - Anonymous Online Contributor
"Although inpatient wards offer significant benefits in preventing relapse, our study provides evidence that a'real world' situation would prove to be a superior 'control' context for studying the impact of preventive treatments." - Anonymous Online Contributor
"Around 18% of patients with first episode depression are likely to relapse within 1 year. If the recurrence is moderate, around 3-4% of relapse patients are likely to relapse within 1 year. Recent findings suggest that relapse is more common in moderate/severe depression than in major depression." - Anonymous Online Contributor
"Many patients with mood disorders have adverse life events during periods of protracted symptoms. For patients in remission it may be helpful to have periodic reassessments to allow preventive measures to be instituted early upon detection of a recurrence." - Anonymous Online Contributor
"Treatment of relapse occurs in the first year following the definitive diagnosis of cancer with most treatments. Current recommendations include chemotherapy based on disease-specific prognostic indicators. Relapse occurs in the majority of patients two years after diagnosis, with half of those patients achieving remission in the interim period." - Anonymous Online Contributor
"Xrd-0394 has been evaluated in the treatment of several types of solid tumors. Recent findings indicates that patients whose disease were responsive to xrd-0394 (that is, disease-free) had a better prognosis than those who were not responsive to xrd-0394. The drug is currently being evaluated in clinical trials for relapsed/refractory Hodgkin lymphoma, solid tumors, and cutaneous lesions. As with other small-molecule inhibitors of retinoic acid, there are risk factors for cardiovascular events associated with xrd-0394 that need to be assessed at the start of the trials." - Anonymous Online Contributor
"In a clinical trial for CTCL, XRD-0394 was well tolerated with no clinically relevant drug-drug interactions. Additionally, significant suppression of peripheral blood NK cells (CD16+CD57+) with XRD-0394 was observed within 3 months of treatment, consistent with the hypothesis that inhibition of NK cells might be the mechanism of action. Based on these findings, clinical trials with XRD-0394, including both single-agent and combination regimens, are in the planning stages for CTCL." - Anonymous Online Contributor
"XRD-0394 is well tolerated. It has a promising pharmacokinetic profile. Mild adverse effects including diarrhea, nausea, headache; and fatigue are most frequently observed. Further studies are needed to establish a precise adverse effect mechanism, and potential clinical effect, of this agent." - Anonymous Online Contributor
"Xrd-0394 significantly enhances the anti-cancer effect of cisplatin, and this effect is achieved with the lowest possible dose, suggesting that xrd-0394 may be used instead of cisplatin as a first-line cancer regimen in patients with a poor survival. Xrd-0394 is effective even in advanced disease because of a good response to this drug in the treatment of metastatic disease." - Anonymous Online Contributor
"Data from a recent study support our hypothesis that xrd-0394 causes an increased amount of XBP1 mRNA, which then causes the transcription factor to bind to the E-box sequence. Once bound to the E-box sequence, XBP1 will then bind to and promote transcription of the XBP-1 gene, which then begins the response to xrd-0394. In a subset of L-cells, xrd-0394 can also induce apoptosis through the modulation of caspases." - Anonymous Online Contributor
"In the last 6 months, one-fifth of the patients who responded to anti-TNFα therapy had a relapse. Clinical trials for relapse were more likely to be eligible for low-risk/low-fat/low-calorie diets, but few of the patients who were eligible for a trial were aware of it and did it. Clinicians may wish to consider conducting a clinical trial for relapse when patients meet these criteria." - Anonymous Online Contributor